How can companies developing drugs for rare diseases and those afflicting smaller patient groups understand patient audiences that are highly underdiagnosed, miscoded and absent in the extant medical literature?
There’s a lot riding on this fundamental question, which can inform everything from go/no go decisions to clinical trial design to value generation and stakeholder engagement efforts.
Download this executive brief to learn:
- Key challenges associated with sizing and segmenting smaller patient groups
- The risks of having inaccurate or incomplete views
- Creative analytical approaches to better understanding patients
